Tissue transglutaminase: a new target to reverse cancer drug resistance
about
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancerCompensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor TreatmentTransglutaminase regulation of cell function.TGM2: a cell surface marker in esophageal adenocarcinomas.Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway.Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitroTransglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.Transglutaminase 2 in cancer.TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated AutophagyTissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.Calyxin Y sensitizes cisplatin-sensitive and resistant hepatocellular carcinoma cells to cisplatin through apoptotic and autophagic cell death via SCF βTrCP-mediated eEF2K degradation.Prognostic role of tissue transglutaminase 2 in colon carcinoma.Effect of retinyl acetate on transglutaminase 2 activity in carcinogen treated rat liver.Transglutaminase 2, a double face enzyme.Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formationA small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells
P2860
Q26824316-C8150316-3A2D-408F-BC3A-FF50B0E6E1AAQ28550149-1C31BBEB-4CB5-41B7-9160-929A49082B5CQ33707936-8BEAE988-6971-4297-BD34-708EC7C65D68Q34219975-1E7B6B8B-8A9E-4306-955C-AAC71537EEC2Q34489967-BFC1DF82-37EB-40A2-90B0-28C710599302Q35164379-6D895376-11B5-45BE-8DC8-37A1CF44D784Q35858675-BEDAD936-3034-42F6-8A73-AA593910BA9AQ36022262-E8457969-0559-4883-B8BE-700E45F12933Q37745215-BE811E26-D720-4916-83E8-29FBEB8BA553Q38648421-F5327F5C-8E40-465C-A71B-D0766136D4B8Q38734433-7E4D4776-9EFF-42B5-BD67-E47A378F6737Q39268578-7CBD9508-2059-40E4-BADF-62100484FAA0Q42378457-D016C6F7-6D9C-4C97-BCCD-EE5D51C49DD1Q51515881-3948A46F-5FFE-4DED-983F-A6428F4492C8Q52874453-2A57A334-6964-4BC0-8FFA-4F13692E0B92Q54433849-C2299004-0F9D-4CE6-936B-03DF948FDC0FQ57818345-526CD417-2141-4022-AA6C-96DAEFE08525Q57821053-1A78922E-05D6-44EA-BF2D-87322E3B1D73
P2860
Tissue transglutaminase: a new target to reverse cancer drug resistance
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Tissue transglutaminase: a new target to reverse cancer drug resistance
@ast
Tissue transglutaminase: a new target to reverse cancer drug resistance
@en
type
label
Tissue transglutaminase: a new target to reverse cancer drug resistance
@ast
Tissue transglutaminase: a new target to reverse cancer drug resistance
@en
prefLabel
Tissue transglutaminase: a new target to reverse cancer drug resistance
@ast
Tissue transglutaminase: a new target to reverse cancer drug resistance
@en
P2860
P1433
P1476
Tissue transglutaminase: a new target to reverse cancer drug resistance
@en
P2093
Alfredo Budillon
Elena Di Gennaro
P2860
P2888
P356
10.1007/S00726-011-1167-9
P577
2011-12-01T00:00:00Z
2013-01-01T00:00:00Z